TENAX THERAPEUTICS, INC. - FORM 10-K - EX-23.1 - CONSENTS OF EXPERTS AND COUNSEL - March 30, 2020

Attached files

file filename
EX-32.2 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - TENAX THERAPEUTICS, INC.tenx_ex322.htm
EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - TENAX THERAPEUTICS, INC.tenx_ex321.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - TENAX THERAPEUTICS, INC.tenx_ex312.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - TENAX THERAPEUTICS, INC.tenx_ex311.htm
10-K - ANNUAL REPORT - TENAX THERAPEUTICS, INC.tenx_10k.htm
 
Exhibit 23.1
 
Consent of Independent Registered Public Accounting Firm
 
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-167175, 333-196464, 333-210182, 333-224120, and 333-233571), Form S-3 (No. 333-224951), and Form S-1 (No. 333-228212) of our report dated March 30, 2020 included in this Annual Report on Form 10-K of Tenax Therapeutics, Inc. and Subsidiary (the “Company”), relating to the consolidated balance sheets of the Company as of December 31, 2019 and 2018, and the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows, and the related notes (which report expresses an unqualified opinion and contains an explanatory paragraph regarding substantial doubt about the Company’s ability to continue as a going concern) for each of the years in the two-year period ended December 31, 2019.
 
/s/ CHERRY BEKAERT LLP
 
Raleigh, North Carolina
March 30, 2020
 
 

TENAX THERAPEUTICS, INC. Reports